GLP-3 vs GLP-1: What the Name Means, How the Mechanisms Differ, and Where Research Stands

When people search for “GLP-3,” they are usually looking for a next step beyond GLP-1 drugs. The first useful step is to translate the name: “GLP-3” is an informal shorthand used in online coverage for investigational medicines that activate three metabolic hormone pathways. It is not the official name of a newer version of the GLP-1 hormone. The most important difference is the receptor targets being studied—not a “1 versus 3” potency scale.

What “GLP-3” usually refers to

The term most often points to a triple agonist such as retatrutide (also called LY3437943). A triple agonist is designed to act at the GLP-1, GIP, and glucagon receptors. That is different from semaglutide, which activates the GLP-1 receptor, and from tirzepatide, which activates GLP-1 and GIP receptors.

The “1” in GLP-1 is part of the hormone’s name; it does not count drug targets. GLP-2 is a different hormone, not a formal name for tirzepatide. Similarly, “GLP-3” is not the official name for the triple-agonist drug class. The number is not a score, a potency rating, or a promise that a medicine works three times as well. It describes the number of receptor pathways being targeted in the shorthand used by popular coverage. The pathways overlap in their effects on appetite, glucose handling, and energy metabolism, but “more targets” does not automatically answer whether a treatment is safer, more effective, or right for a particular person.

GLP-1, dual agonists, and triple agonists

GLP-1 signaling can increase glucose-dependent insulin secretion, reduce appetite, and slow stomach emptying. GIP signaling may add effects on insulin response and energy balance. Glucagon signaling is being studied for its effects on energy expenditure and liver metabolism. The real clinical question is how the combined biology behaves in people over time, including tolerability and risks—not how impressive the nickname sounds.

Where retatrutide research stands

The phase 2 retatrutide obesity trial was published in the New England Journal of Medicine in 2023. It enrolled 338 adults with a BMI of at least 30, or a BMI of 27 to less than 30 plus a weight-related condition. Participants received retatrutide or placebo for 48 weeks.

In the highest studied dose group, the estimated average weight change at 48 weeks was a 24.2% reduction, compared with a 2.1% reduction with placebo. This was a group average under the study’s conditions, not a prediction for an individual. The study compared retatrutide with placebo; it did not establish superiority over semaglutide or tirzepatide in a direct comparison.

The most common adverse events were gastrointestinal, were dose-related, and were mostly mild to moderate. Dose-dependent increases in heart rate were also observed. Those findings are part of the result, alongside the weight change. This article does not translate trial doses into a self-treatment schedule.

ClinicalTrials.gov lists the TRIUMPH-1 retatrutide study as a completed phase 3 study, with the record updated in August 2026. The record describes an approximately 89-week study with up to 24 visits and an optional extension. The TRIUMPH-1 registry record, last updated August 21, 2026, did not have results posted when checked for this article on October 26, 2026. That does not mean no results have been announced elsewhere. A completed study record still does not mean the product is approved or available by prescription. Approval requires regulators to review the complete evidence and authorize a specific product, indication, dose, and labeling.

Why research status matters

An investigational compound is not interchangeable with an approved GLP-1 medicine. Online sellers may use “GLP-3” as a marketing term, but a label or social post cannot establish identity, quality, sterility, dose accuracy, or FDA authorization. Do not use research protocols to choose a dose or source a compound.

For a current status check, use the FDA’s drug information and approval databases and the ClinicalTrials.gov record rather than a countdown article. A headline can be outdated even when the underlying study is real.

Does targeting three receptors mean better treatment?

Not by itself. A useful comparison would ask whether the treatments were tested against each other, in similar people, for the same duration and outcome. A percentage from an early trial and a percentage from a different product’s trial cannot settle that question. Long-term safety, stopping treatment because of adverse effects, and benefits for the condition being treated also matter.

For the basic biology of established GLP-1 therapy, see how GLP-1 medicines work. That is a different question from whether a particular triple agonist has completed the evidence and regulatory steps needed for routine prescribing.

The practical comparison to make

If your question is about a prescription you can discuss now, compare the exact approved product: its active ingredient, indication, form, dosing instructions, contraindications, and current prescribing information. If your question is about what may come next, separate three things: the receptor mechanism, the trial evidence, and the regulatory status.

That separation keeps an exciting research result in proportion. GLP-3 is a useful search term for a research direction. It is not a shortcut around the ordinary work of checking a medicine’s label and having a focused conversation with a qualified prescriber.